Cheyenne Regional Medical Center Successfully Performs Wyoming’s First AVEIR™ Leadless Pacemaker Implants

Cheyenne Regional Medical Center today announced the successful completion of Wyoming’s first AVEIR™ leadless pacemaker implants from Abbott, including two AVEIR AR2™ atrial leadless pacemakers and one AVEIR™ DR dual chamber leadless pacemaker system. The groundbreaking technology, approved by the U.S. Food and Drug Administration (FDA) in June 2023, provides Cheyenne Regional Medical Center with new minimally invasive options to treat people with abnormal or slow heart rhythms.

Unlike traditional pacemakers, leadless devices are implanted directly into the heart through a minimally invasive procedure and eliminate the need for cardiac leads. As a result, leadless pacemakers reduce people’s exposure to potential lead- and pocket-related complications and offer a less restrictive and shorter recovery period post-implantation.

Roughly one-tenth the size of a traditional pacemaker, the AVEIR DR dual chamber leadless pacing system is made up of two devices – the AVEIR VR ventricular leadless pacemaker, which paces the right ventricle (VR), and the AVEIR AR atrial leadless pacemaker, which paces the right atrium (AR). AVEIR incorporates Abbott’s novel i2i technology, which solves a significant engineering challenge by offering beat-to-beat communication between the two leadless pacemakers.

“We are proud to be the first team in Wyoming to offer Abbott’s groundbreaking dual chamber leadless pacemaker system. It is estimated that millions of people across the U.S. require pacing in both chambers of the heart, and AVEIR DR gives us another innovative option to help improve the lives of our patients while advancing our mission to inspire great health,” said Dr. Daniel Wann, electrophysiologist at Cheyenne Regional Medical Center’s Heart & Vascular Institute.